Zobrazeno 1 - 10
of 42
pro vyhledávání: ''
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Hisashi Motomura, Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Shuhei Tomita, Koji Takada, Masahiko Ohsawa, Katsuyuki Takahashi, Kosei Hirakawa, Masaichi Ohira, Tsutomu Takashima, Takaharu Hatano
Publikováno v:
British Journal of Cancer
Background Immune responses in a tumour microenvironment can be evaluated by analysing tumour-infiltrating lymphocyte (TIL) density; this has been verified in the clinical setting. Although there are many reports on TIL density in primary tumours, li
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
Autor:
Agnes Jager, Nyrée Smallenbroek, Caroline M. Seynaeve, Jan C. Drooger, Cynthia Epskamp, Bernadette A M Heemskerk-Gerritsen
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 156(3), 557-566. Springer New York
Breast Cancer Research and Treatment, 156(3), 557-566. Springer New York
Treatment with (neo)adjuvant chemotherapy for breast cancer, as currently given, causes cell damage by induction of double-strand DNA breaks. Because BRCA1 and BRCA2 proteins play a role in the repair of DNA damage, the efficacy of (neo)adjuvant chem
Autor:
Sally Tan, Pasi A. Jänne, John J. Wright, Katherine Larrabee, Hao Guo, Eric P. Winer, Sara M. Tolaney, Eliezer M. Van Allen, Elena Ivanova, Ian E. Krop, Beth Overmoyer, William H. Barry, Jane E. Brock, Geoffrey I. Shapiro, Cloud P. Paweletz, Nikhil Wagle
Publikováno v:
Investigational New Drugs
SummaryBackground MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests t
Autor:
Jae Hoo Park, In Sil Choi, In Hae Park, Jee Hyun Kim, Ki Hyeong Lee, Hee Jun Kim, Keon Uk Park, Hye Sook Han, Jiyeon Kim, So Young Yoon, Seock-Ah Im, Si Young Kim, Kyung Hae Jung, Moon Hee Lee, Eun Kyung Cho, Young Jin Choi, Joo Han Lim, Do-Youn Oh
Publikováno v:
Supportive Care in Cancer
Purpose Pegylated granulocyte-colony-stimulating factor (G-CSF) is frequently used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy with a high risk of myelosuppression. This phase II/III study was conducted to determine the ad
Publikováno v:
Pathology Oncology Research
A considerable subgroup of patients with early breast cancer does not address benefits of anthracycline based chemotherapy. The aim of this retrospective study was to investigate the effect of microvessel density (MVD) and status of p53 protein on 5-
Autor:
William E. Barlow, Stanley Vogel, Kristine Rinn, Kim Z Dammann, Danika Lew, Gabriel N. Hortobagyi, Julie R. Gralow, Robert B. Livingston, George Somlo, Lucas Wong
Publikováno v:
Breast Cancer Research and Treatment
Docetaxel and vinorelbine have demonstrated Single-agent activity in breast cancer. Preclinical studies suggest potential synergy between these antitubulin chemotherapy agents. This study evaluates these drugs in combination in metastatic breast canc
A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer
Publikováno v:
Clinical & Translational Oncology
Purpose To explore the association between the 3,144 m/z protein peak and the clinicopathological features and prognosis in breast cancer. Methods Using SELDI–TOF MS, we analyzed serum protein peak at 3,144 m/z in 283 patients with node-positive br